Open Studies

Protocol
Title
Target
accrual
EORTC Boron Neutron Capture Therapy Group (closed group)
11001
10B-uptake in different tumours using the boron compounds BSH and BPA.
27
EORTC Brain Tumor Group
16027
26023
Phase I study of SCH66336(lonafarnib), a farnesyl protein transferase inhibitor in combination with temozolomide in gliomas
25
22033
26033
Primary chemotherapy with temozolomide vs.radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss : a phase III study
700
22042
26042
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma : a Phase II and observation study
77
26053
22054
Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.
748
26054
Phase I study of LY317615 (Enzastaurin) and temozolomide in patients with gliomas
40
26071
22072
Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone.
504
EORTC Breast Cancer Group
10031
IBCSG 24-02
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane
3000
10041
MINDACT
MINDACT (Microarray In Node-negative Disease may avoid Chemotherapy): A prospective, randomised study comparing the 70-gene signature with the common clinic-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer.
6000
10053
Pharmacokinetics study of combined treatment Lapatinib and Tamoxifen in advanced/metastatic breast cancer
20
10054
A phase I-II study of Lapatinib and Docetaxel as neoadjuvant treatment for locally advanced breast cancer.
114
10071
A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
8000
10981
22023
After Mapping of the Axilla:Radiotherapy Or Surgery AMAROS
3485
22051
10052
Selective Use of Postoperative Radiotherapy AftEr MastectOmy
3700
EORTC Children's Leukemia Group
58051
Interfant
International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia
445
EORTC Cutaneous Lymphoma Task Force
21011
A randomised, open-label phase III trial to evaluate the efficacy and safety of Bexarotene (Targretin TM) capsules combined with PUVA, compared to PUVA treatment alone in patients with Mycosis Fungoides.
140
21012
Phase II clinical trial with Caelyx mono-chemotherapy in patients with advanced Mycosis Fungoides stage IIb, IVa and IVb with or without previous chemotherapy.
48
EORTC Gastrointestinal Tract Cancer Group
40051
BOS
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer.
100
40052
PETACC-8
Adjuvant treatment of fully resected stage III colon cancer with folfox-4 versus folfox-4 plus cetuximab (PETACC-8)
2000
40054
22062
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaplatin vs.capecitabine alone in locally advanced rectal cancer (PETACC-6).
1090
EORTC Genito-Urinary Tract Cancer Group
30061
Phase I study of cisplatin, gemcitabine (+ paclitaxel) and lapatinib as first line treatment in advanced/metastatic urothelial cancer
30983
Randomized phase II/III study of Taxol-BEP versus BEP in patients with intermediate prognosis germ cell cancer
498
EORTC Gynecological Cancer Group
55994
Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherpy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.
686
EORTC Head and Neck Cancer Group
24061
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies
55
EORTC Infectious Diseases Group
65031
Fungemia Survey in Cancer Patients
EORTC Leukemia Group
06031
AML-19
Gemtuzumab ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy : a randomized phase II/III trial (AML-19) of the EORTC-LG and GIMEMA-ALWP.
260
06061
AML-14
Clofarabine in combination with a standard remissioninduction regimen (AraC and idarubicin) in patients 18-60 years old with previously untreated intermediate and bad risk acute myelogenous leukemia (AML) or high risk myelodysplasia (MDS) : a phase I-II study of the EORTC-LG and GIMEMA (AML-14A trial)
120
EORTC Lung Cancer Group
08052
Phase II study of bortezomib with cisplatin as first line treatment of malignant mesothelioma
76
08062
Randomization phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES).
81
08072
22074
Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status
532
EORTC Lymphoma Group
20012
BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's Lymphoma
550
20051
H10
The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma.
1576
20971
22997
A Phase III randomized study on low-dose total body irradiation and involved field radiotherapy in patients with localized, stages I and II, low grade non-Hodgkin's lymphoma
344
EORTC Melanoma Group
18021
Intravenous versus intra-arterial fotemustine chemotherapy in patients with liver metastases from uveal melanoma : a randomized phase III study of the EORTC Melanoma Group.
262
18071
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (iîlimumab) versus placebo after complete resection of high-risk Stage III melanoma : A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.
950
EORTC New Drug Development Group (closed group)
16027
26023
Phase I study of SCH66336(lonafarnib), a farnesyl protein transferase inhibitor in combination with temozolomide in gliomas
25
EORTC Radiation Oncology Group
08072
22074
Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status
532
10981
22023
After Mapping of the Axilla:Radiotherapy Or Surgery AMAROS
3485
20971
22997
A Phase III randomized study on low-dose total body irradiation and involved field radiotherapy in patients with localized, stages I and II, low grade non-Hodgkin's lymphoma
344
22033
26033
Primary chemotherapy with temozolomide vs.radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss : a phase III study
700
22042
26042
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma : a Phase II and observation study
77
22051
10052
Selective Use of Postoperative Radiotherapy AftEr MastectOmy
3700
26053
22054
Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON intergroup trial.
748
26071
22072
Cilengitide in subjects with newly diagnosed glioblastoma and methylated MGMT promoter gene- a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone.
504
40054
22062
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaplatin vs.capecitabine alone in locally advanced rectal cancer (PETACC-6).
1090
EORTC Soft Tissue and Bone Sarcoma Group
62012
Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma
450
62052
Phase II study of E7389 administered as an IV infusion on day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma
148
62072
A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy.
255

41 studies

06/01/2009 09:48:57